Bristol-Myers Squibb Co. (NYSE:BMY) finished Wednesday with a subtraction of -$0.65 to close at $57.89, a downside of -1.11 percent. An average of 9,108,240 shares of common stock have been traded in the last five days. There was a fall of -$0.89 in the past week, and it reached a new high 13 times over the past 12 months. The last 20 days have seen an average of 11,777,940 shares traded, while the 50-day average volume stands at 11,434,046.
BMY stock has decreased by -6.08% in the last month. The company shares reached their 1-month lowest point of $57.61 on 09/27/23. With the stock rallying to its 52-week high on 02/06/23, shares of the company touched a low of $58.33 and a high of $81.43 in 52 weeks. It has reached a new high 9 times so far this year and lost -19.54% or -$14.06 in price. In spite of this, the price is down -28.91% from the 52-week high.
Insider Transactions
BMY stock investors should be aware that Bristol-Myers Squibb Co. (BMY) stock had its last reported insider trading activity 35 days ago on Aug 24. In this transaction, the insider spent $1,101,642. EVP, Chief Research Officer, Plenge Robert M, disposed of 732 shares at a price of $61.14 on Aug 03. The insider now owns more than $44,754 worth of shares. Prior to that, EVP & President, Research VESSEY RUPERT went on to Sale 50,385 shares at $67.06 each on May 03. An amount of $3,378,818 was transacted.
Valuation Metrics
Bristol-Myers Squibb Co. (BMY) has a trailing price-to-earnings (P/E) ratio of 15.41. The stock’s beta is 0.42. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.68, the price-to-book (PB) ratio at 3.78, and the price-to-cash flow ratio at 11.28.
Financial Health
The quick ratio of Bristol-Myers Squibb Co. for the recent quarter was 1.28, and the current ratio was 1.39, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.13 and a total debt to equity ratio of 1.23 for the recent quarter. Its gross profit as reported stood at $36.02 billion compared to revenue of $46.16 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Bristol-Myers Squibb Co.’s return on assets was 8.22%.
Earnings Surprise
For the recent quarter, Bristol-Myers Squibb Co. had $34.66 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $2.07 billion in the quarter, while revenues of $2.26 billion were grew 31.45%. Shareholders own equity worth $2.09 billion.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Bristol-Myers Squibb Co. (BMY) price momentum. RSI 9-day as of the close on 27 September was 27.83%, suggesting the stock is oversold, with historical volatility in this time frame at 9.34%.
As of today, BMY’s price is $58.71 -1.51% or -$0.89 from its 5-day moving average. BMY is currently trading -7.89% lower than its 20-day SMA and -13.36% lower than its 100-day SMA. However, the stock’s current price level is -6.63% below the SMA50 and -27.53% below the SMA200.
The stochastic %K and %D were 13.65% and 16.76%, respectively, and the average true range (ATR) was 0.89. With the 14-day stochastic at 7.34% and the average true range at 0.92, the RSI (14) stands at 32.40%. The stock has reached -0.20 on the 9-day MACD Oscillator while the 14-day reading was at -0.73.
Analyst Ratings
HSBC Securities launched coverage on Bristol-Myers Squibb Co. (NYSE: BMY) in its analyst report released on July 14, 2023. The firm assigned the stock a Reduce rating. The consensus rating for Bristol-Myers Squibb Co. (BMY) among analysts is Overweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell BMY, while 11 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 12 others rate it as a “buy”.
What is BMY’s price target for the next 12 months?
Analysts predict a range of price targets between $55.00 and $90.00, with a median target of $74.00. Taking a look at these predictions, the average price target given by analysts for Bristol-Myers Squibb Co. (BMY) stock is $72.90.
